Skip to main content

Closed

ERNA: Ernexa Therapeutics Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-100.0% / yr

Operating margin0.0%

ROIC-138.7%

Financially safe

Stretched

Debt / equity0.06×

Interest coverage-326.9×

Current ratio2.89×

Ernexa Therapeutics Inc.

ERNANASDAQ Global Market·USD·Closed

Ernexa Therapeutics Inc.

ERNANASDAQ·USD·Closed

$3.28

−5.48%

$3.28

−$0.19 (5.48%)

52W Range

0thpctl

Volume

0.01×avg

Mkt Cap

1.03MUSD

P/E

-0.1TTM

Div Yield

–ann

52W Range

0thpctl

Volume

0.01×avg

Market Cap

1.03MUSD

P/E Ratio

-0.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings